TY - JOUR
T1 - Prediagnostic blood selenium status and mortality among patients with colorectal cancer in western european populations
AU - Baker, Jacqueline Roshelli
AU - Umesh, Sushma
AU - Jenab, Mazda
AU - Schomburg, Lutz
AU - Tjønneland, Anne
AU - Olsen, Anja
AU - Boutron-Ruault, Marie Christine
AU - Rothwell, Joseph A.
AU - Severi, Gianluca
AU - Katzke, Verena
AU - Johnson, Theron
AU - Schulze, Matthias B.
AU - Masala, Giovanna
AU - Agnoli, Claudia
AU - Simeon, Vittorio
AU - Tumino, Rosario
AU - Bueno-De-mesquita, H. Bas
AU - Gram, Inger Torhild
AU - Skeie, Guri
AU - Bonet, Catalina
AU - Rodriguez-Barranco, Miguel
AU - Houerta, José María
AU - Gylling, Björn
AU - Van Guelpen, Bethany
AU - Perez-Cornago, Aurora
AU - Aglago, Elom
AU - Freisling, Heinz
AU - Weiderpass, Elisabete
AU - Cross, Amanda J.
AU - Heath, Alicia K.
AU - Hughes, David J.
AU - Fedirko, Veronika
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11
Y1 - 2021/11
N2 - A higher selenium (Se) status has been shown to be associated with lower risk for colorectal cancer (CRC), but the importance of Se in survival after CRC diagnosis is not well studied. The associations of prediagnostic circulating Se status (as indicated by serum Se and selenoprotein P (SELENOP) measurements) with overall and CRC-specific mortality were estimated using multi-variable Cox proportional hazards regression among 995 CRC cases (515 deaths, 396 from CRC) in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Se and SELENOP serum concentrations were measured on average 46 months before CRC diagnosis. Median follow-up time was 113 months. Participants with Se concentrations in the highest quintile (≥100 µg/L) had a multivariable-adjusted hazard ratio (HR) of 0.73 (95% CI: 0.52–1.02; Ptrend = 0.06) for CRC-specific mortality and 0.77 (95% CI: 0.57–1.03; Ptrend = 0.04) for overall mortality, compared with the lowest quintile (≤67.5 µg/L). Similarly, participants with SELENOP concentrations in the highest (≥5.07 mg/L) compared with the lowest quintile (≤3.53 mg/L) had HRs of 0.89 (95% CI: 0.64–1.24; Ptrend = 0.39) for CRC-specific mortality and 0.83 (95% CI: 0.62–1.11; Ptrend = 0.17) for overall mortal-ity. Higher prediagnostic exposure to Se within an optimal concentration (100–150 µg/L) might be associated with improved survival among CRC patients, although our results were not statistically significant and additional studies are needed to confirm this potential association. Our findings may stimulate further research on selenium’s role in survival among CRC patients especially among those residing in geographic regions with suboptimal Se availability.
AB - A higher selenium (Se) status has been shown to be associated with lower risk for colorectal cancer (CRC), but the importance of Se in survival after CRC diagnosis is not well studied. The associations of prediagnostic circulating Se status (as indicated by serum Se and selenoprotein P (SELENOP) measurements) with overall and CRC-specific mortality were estimated using multi-variable Cox proportional hazards regression among 995 CRC cases (515 deaths, 396 from CRC) in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Se and SELENOP serum concentrations were measured on average 46 months before CRC diagnosis. Median follow-up time was 113 months. Participants with Se concentrations in the highest quintile (≥100 µg/L) had a multivariable-adjusted hazard ratio (HR) of 0.73 (95% CI: 0.52–1.02; Ptrend = 0.06) for CRC-specific mortality and 0.77 (95% CI: 0.57–1.03; Ptrend = 0.04) for overall mortality, compared with the lowest quintile (≤67.5 µg/L). Similarly, participants with SELENOP concentrations in the highest (≥5.07 mg/L) compared with the lowest quintile (≤3.53 mg/L) had HRs of 0.89 (95% CI: 0.64–1.24; Ptrend = 0.39) for CRC-specific mortality and 0.83 (95% CI: 0.62–1.11; Ptrend = 0.17) for overall mortal-ity. Higher prediagnostic exposure to Se within an optimal concentration (100–150 µg/L) might be associated with improved survival among CRC patients, although our results were not statistically significant and additional studies are needed to confirm this potential association. Our findings may stimulate further research on selenium’s role in survival among CRC patients especially among those residing in geographic regions with suboptimal Se availability.
KW - Cohort
KW - Colorectal cancer
KW - Selenium
KW - Selenoprotein P
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85118387477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118387477&partnerID=8YFLogxK
U2 - 10.3390/biomedicines9111521
DO - 10.3390/biomedicines9111521
M3 - Article
C2 - 34829750
AN - SCOPUS:85118387477
SN - 2227-9059
VL - 9
JO - Biomedicines
JF - Biomedicines
IS - 11
M1 - 1521
ER -